Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

Mature HIV-like Particles Produced from Single Semliki Forest Virus-Derived Expression Vector

  • KIM EUN (Laboratory of Infectious Disease, College of Veterinary Medicine, Chungnam National University) ;
  • POO HAR-YOUNG (Proteome Research Lab., Korea Research Institute of Bioscience and Biotechnology) ;
  • SUNG MOON-HEE (Department of Bio & Nanochemisty, College of Natural Sciences, Kookmin University) ;
  • KIM CHUL-JOONG (Laboratory of Infectious Disease, College of Veterinary Medicine, Chungnam National University)
  • Published : 2005.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Human immunodeficiency virus-like particles (HIVVLPs) with native conformations similar to that of the wild-type virion could be valid candidates for vaccine development. To this end, we used a Semliki Forest Virus (SFV) expression system to produce HIV- VLPs containing high quantities of native envelope proteins. Here, we described a single SFV replicon containing the HIV gagpol and env genes under the control of separate subgenomic promoters. Mature VLPs incorporating the Gag and Env proteins were detected in the supernatant of replicon-expressing cells by Western blot analysis. The HIV-VLPs showed the expected molecular density (1.14-1.18 g/ml) on a $20-60\%$ sucrose gradient; the particles were 100-120 nm in diameter and Env proteins were observed on their surfaces by immunogold electron microscopy. RT-PCR analysis of VLP-associated RNAs in mature HIV-VLPs revealed two SF V-derived RNA species (full-length and subgenomic). Immunization studies in Balb/c mice showed that these HIV-VLPs were capable of inducing both HIV-specific antibodies and cell-mediated immune responses. Taken together, our results indicate that the SFV replicon system is useful for the production of HIV-VLPs, which may be valuable candidates for an HIV vaccine.

Keywords

References

  1. Abel, K., L. Compton, T. Rourke, D. Montefiori, D. Lu, K. Rothaeusler, L. Fritts, K. Bost, and C. J. Miller. 2003. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J. Virol. 77: 3099-3118 https://doi.org/10.1128/JVI.77.5.3099-3118.2003
  2. Adamson, C. S., A. Davies, Y. Soneoka, M. Nermut, K. Mitrophanous, and I. M. Jones. 2003. A block in virus-like particle maturation following assembly of murine leukaemia virus in insect cells. Virology 314: 488-496 https://doi.org/10.1016/S0042-6822(03)00485-9
  3. Berglund, P., M. Quesada-Rolander, P. Putkonen, G. Biberfeld, R. Thorstensson, and P. Liljestrom. 1997. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retroviruses 13: 1487- 1495 https://doi.org/10.1089/aid.1997.13.1487
  4. Campbell, S. and A. Rein. 1999. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J. Virol. 73: 2270-2299
  5. Choi, E. A., E. Kim, Y. I. Oh, K. S. Shin, H. S. Kim, and C. J. Kim. 2002. Expression of rotavirus capsid proteins VP6 and VP7 in mammalian cells using Semliki Forest virusbased expression system. J. Microbiol. Biotechnol. 12: 463-469
  6. Deml, L., G. Kratochwil, N. Osterrieder, R. Knuchel, H. Wolf, and R. Wagner. 1997. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 235: 10-25 https://doi.org/10.1006/viro.1997.8669
  7. Deml, L., R. Schirmbeck, J. Reimann, H. Wolf, and R. Wagner. 1997. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 235: 26-39 https://doi.org/10.1006/viro.1997.8668
  8. Fleeton, M. N., P. Liljestrom, B. J. Sheahan, and G. J. Atkins. 2000. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J. Gen. Virol. 81: 749-758 https://doi.org/10.1099/0022-1317-81-3-749
  9. Gao, F., Y. Li, J. M. Decker, F. W. Peyerl, F. Bibollet-Ruche, C. M. Rodenburg, Y. Chen, D. R. Shaw, S. Allen, R. Musonda, G. M. Shaw, A. J. Zajac, N. Letvin, and B. H. Hahn. 2003. Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: In vitro expression and immune responses in DNA-vaccinated mice. AIDS Res. Hum. Retroviruses 19: 817-823 https://doi.org/10.1089/088922203769232610
  10. Golding, B., N. Eller, L. Levy, P. Beining, J. Inman, N. Matthews, D. E. Scott, and H. Golding. 2002. Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus. Vaccine 20: 1445-1450 https://doi.org/10.1016/S0264-410X(01)00477-7
  11. Gonzalo, R. M., D. Rodriguez, A. Garcia-Sastre, J. R. Rodriguez, P. Palese, and M. Esteban. 1999. CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17: 887-892 https://doi.org/10.1016/S0264-410X(98)00274-6
  12. Gzyl, J., E. Bolesta, A. Wierzbicki, D. Kmieciak, T. Naito, M. Honda, K. Komuro, Y. Kaneko, and D. Kozbor. 2004. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses. Virology 318: 493-506 https://doi.org/10.1016/j.virol.2003.10.009
  13. Hamajima, K., Y. Hoshino, K. Q. Xin, F. Hayashi, K. Tadokoro, and K. Okuda. 2002. Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine. Clin. Immunol. 102: 12-18 https://doi.org/10.1006/clim.2001.5141
  14. Hanke, T., C. Barnfield, E. G. Wee, L. Agren, R. V. Samuel, N. Larke, and P. Liljestrom. 2003. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J. Gen. Virol. 84: 361- 368 https://doi.org/10.1099/vir.0.18738-0
  15. Heeney, J. L., G. Koopman, B. Rosenwirth, W. Bogers, J. van Dijk, I. Nieuwenhuis, H. Niphuis, P. ten Haaft, T. Hanke, G. Rhodes, P. Berglund, A. Burny, F. Bex, G. Sutter, and P. Liljestrom. 2000. A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens. J. Med. Primatol. 29: 268-273 https://doi.org/10.1034/j.1600-0684.2000.290320.x
  16. Hewer, R. and D. Meyer. 2003. Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/ AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits. Mol. Immunol. 40: 327-335 https://doi.org/10.1016/S0161-5890(03)00163-9
  17. Hofmann-Lehmann, R., J. Vlasak, A. L. Williams, A. L. Chenine, H. M. McClure, D. C. Anderson, S. O'Neil, and R. M. Ruprecht. 2003. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17: 157-166 https://doi.org/10.1097/00002030-200301240-00004
  18. Iida, T., T. Kuwata, M. Ui, H. Suzuki, T. Miura, K. Ibuki, H. Takahashi, T. Yamamoto, J. Imanishi, M. Hayami, and M. Kita. 2004. Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a liveattenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma. Arch. Virol. 149: 743-757 https://doi.org/10.1007/s00705-003-0229-z
  19. Jacks, T., M. D. Power, F. R. Masiarz, P. A. Luciw, P. J. Barr, and H. E. Varmus. 1988. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331: 280-283 https://doi.org/10.1038/331280a0
  20. Kallinteris, N. L., X. Lu, S. Wu, H. Hu, Y. Li, J. V. Gulfo, R. E. Humphreys, and M. Xu. 2003. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 21: 4128- 4132 https://doi.org/10.1016/S0264-410X(03)00493-6
  21. Kim, B. G., H. S. Jeong, S. Y. Baek, J. H. Shin, J. O. Kim, K. I. Min, S. R. Ryu, B. S. Min, D. K. Kim, Y. S. Jeong, and S. N. Park. 2005. Validation of one-step real-time RT-PCR assay in combination with automated RNA extraction for rapid detection and quantitation of Hepatitis C virus RNA for routine testing in clinical specimens. J. Microbiol. Biotechnol. 15: 595-602
  22. Kim, H., S. J. Kim, S. N. Park, and J. W. Oh. 2004. Antiviral effect of Amphotericin B on Japanese Encephalitis virus replication. J. Microbiol. Biotechnol. 14: 121-127
  23. Kong, W. P., Y. Huang, Z. Y. Yang, B. K. Chakrabarti, Z. Moodie, and G. J. Nabel. 2003. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77: 12764-12772 https://doi.org/10.1128/JVI.77.23.12764-12772.2003
  24. Li, K. J. and H. Garoff. 1996. Production of infectious recombinant Moloney murine leukemia virus particles in BHK cells using Semliki Forest virus-derived RNA expression vectors. Proc. Natl. Acad. Sci. USA 93: 11658-11663
  25. Liljestrom, P. and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N.Y.) 9: 1356-1361 https://doi.org/10.1038/nbt1291-1356
  26. Lorin, C., L. Mollet, F. Delebecque, C. Combredet, B. Hurtrel, P. Charneau, M. Brahic, and F. Tangy. 2004. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78: 146-157 https://doi.org/10.1128/JVI.78.1.146-157.2004
  27. Luo, L., Y. Li, and C. Y. Kang. 2003. Budding and secretion of HIV Gag-Env virus-like particles from recombinant human adenovirus infected cells. Virus Res. 92: 75-82 https://doi.org/10.1016/S0168-1702(02)00316-7
  28. Mata, M., P. J. Travers, Q. Liu, F. R. Frankel, and Y. Paterson. 1998. The MHC class I-restricted immune response to HIVgag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J. Immunol. 161: 2985-2993
  29. McGettigan, J. P., K. Naper, J. Orenstein, M. Koser, P. M. McKenna, and M. J. Schnell. 2003. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J. Virol. 77: 10889-10899 https://doi.org/10.1128/JVI.77.20.10889-10899.2003
  30. Mossman, S. P., F. Bex, P. Berglund, J. Arthos, S. P. O'Neil, D. Riley, D. H. Maul, C. Bruck, P. Momin, A. Burny, P. N. Fultz, J. I. Mullins, P. Liljestrom, and E. A. Hoover. 1996. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J. Virol. 70: 1953-1960
  31. Muriaux, D., J. Mirro, D. Harvin, and A. Rein. 2001. RNA is a structural element in retrovirus particles. Proc. Natl. Acad. Sci. USA 98: 5246-5251
  32. Mwau, M., I. Cebere, J. Sutton, P. Chikoti, N. Winstone, E. G. Wee, T. Beattie, Y. H. Chen, L. Dorrell, H. McShane, C. Schmidt, M. Brooks, S. Patel, J. Roberts, C. Conlon, S. L. Rowland-Jones, J. J. Bwayo, A. J. McMichael, and T. Hanke. 2004. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85: 911-919 https://doi.org/10.1099/vir.0.19701-0
  33. Nilsson, C., B. Makitalo, P. Berglund, F. Bex, P. Liljestrom, G. Sutter, V. Erfle, P. ten Haaft, J. Heeney, G. Biberfeld, and R. Thorstensson. 2001. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19: 3526- 3536 https://doi.org/10.1016/S0264-410X(01)00034-2
  34. Ohagen, A., R. B. Luftig, A. S. Reicin, L. Yin, K. Ikuta, T. Kimura, S. P. Goff, and S. Hoglund. 1997. The morphology of the immature HIV-1 virion. Virology 228: 112-114 https://doi.org/10.1006/viro.1996.8362
  35. Perri, S., C. E. Greer, K. Thudium, B. Doe, H. Legg, H. Liu, R. E. Romero, Z. Tang, Q. Bin, T. W. Jr. Dubensky, M. Vajdy, G. R. Otten, and J. M. Polo. 2003. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77: 10394-10403 https://doi.org/10.1128/JVI.77.19.10394-10403.2003
  36. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335 https://doi.org/10.1038/415331a
  37. Vignuzzi, M., S. Gerbaud, S. van der Werf, and N. Escriou. 2001. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J. Gen. Virol. 82: 1737-1747 https://doi.org/10.1099/0022-1317-82-7-1737
  38. Wagner, R., L. Deml, R. Schirmbeck, M. Niedrig, J. Reimann, and H. Wolf. 1996. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology 220: 128-140 https://doi.org/10.1006/viro.1996.0293
  39. Yao, Q., F. M. Kuhlmann, R. Eller, R. W. Compans, and C. Chen. 2000. Production and characterization of simianhuman immunodeficiency virus-like particles. AIDS Res. Hum. Retroviruses 16: 227-236 https://doi.org/10.1089/088922200309322
  40. Yao, Q., V. Vuong, M. Li, and R. W. Compans. 2002. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 20: 2537-2545 https://doi.org/10.1016/S0264-410X(02)00160-3